Opus Genetics

Opus Genetics Net Debt per Share

The Net Debt per Share of Opus Genetics (IRD) as of Nov 1, 2026 is -0.64 USD. In the previous year, Net Debt per Share was -0.44 USD — a change of 44.98% (lower).

Net Debt per Share

-0.64USD

YoY

44.98%

Last updated:

Net Debt per Share of Opus Genetics is 2025 -0.64 USD. Net Debt per Share of Opus Genetics was 2024 -0.44 USD. It decreases by 44.98% lower compared to the previous year.

The Opus Genetics Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
-0.21 USD
Jan 1, 2019
-0.02 USD
Jan 1, 2020
-0.24 USD
Jan 1, 2021
-0.35 USD
Jan 1, 2022
-0.62 USD
Jan 1, 2023
-0.73 USD
Jan 1, 2024
-0.44 USD
Jan 1, 2025
-0.64 USD
The Opus Genetics Net Debt per Share history
YEARNet Debt per ShareYoY
-0.64USD+44.98%
-0.44USD-39.97%
-0.73USD+18.35%
-0.62USD+76.28%
-0.35USD+47.65%
-0.24USD+966.95%
-0.02USD-89.57%
-0.21USD-45.10%
-0.39USD+32.04%
-0.29USD-13.31%
-0.34USD-28.32%
-0.47USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Opus Genetics Stock analysis

What does Opus Genetics do? Ocuphire Pharma, Inc. is a health care company based in Farmington Hills, Michigan, specializing in the research and development of ophthalmic biopharmaceuticals. Listed on the market on 30 November 2004, the firm focuses on therapies for refractive and retinal eye disorders. Its pipeline features Nyxol Eye Drops, a once-daily formulation of phentolamine mesylate aimed at reducing pupil diameter and improving visual acuity for conditions such as presbyopia and night vision disturbances. Additionally, the company develops APX3330, an oral tablet targeting retinal and choroidal diseases, alongside in-licensed second-generation candidates APX2009 and APX2014. The organization employs a small team dedicated to advancing these innovative treatments. Opus Genetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Opus Genetics stock

Net Debt per Share of Opus Genetics is -0.64 USD in 2025.

Net Debt per Share of Opus Genetics changed from -0.44 USD to -0.64 USD, representing a 44.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Opus Genetics since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Opus Genetics

All Key Metrics — Opus Genetics